Increased expression of CD36 and CD163 in clear cell renal cell carcinoma suggests an association between lipid transport and an “M2-like” macrophage phenotype

Lipid metabolic markers CD36 and CD147 are expressed in ccRCC tumors and correlations with immune cell subsets suggest their role in suppressing anti-tumor immunity. These findings suggest the existence of a metabolic-immune axis in ccRCC and provide a rationale for targeting TAM metabolism to enhance immunotherapeutic efficacy.